Cost-Effectiveness of Endoscopic Screening Followed by Surveillance for Barrett's Esophagus: A Review

Gastroenterology

Volumn 137, Issue 6, 2009, Pages 1869-1876

  Barbiere, Josephine M ^a   Lyratzopoulos, Georgios ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BARRETT ESOPHAGUS; COST EFFECTIVENESS ANALYSIS; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; PRIORITY JOURNAL; SCREENING TEST;

EID: 70649111367     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.10.011     Document Type: Article

References (57)

1. Thomas T., Abrams K.R., De Caestecker J.S., et al. Meta analysis: cancer risk in Barrett's Oesophagus. Aliment Pharmacol Ther 26 (2007) 1465-1477
2. Lepage C., Rachet B., Jooste V., et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 103 (2008) 2694-2699
3. Newnham A., Quinn M.J., Babb P., et al. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. Aliment Pharmacol Ther 17 (2003) 665-676
4. Sihvo E.I., Salminen J.T., Rämö O.J., et al. The epidemiology of oesophageal adenocarcinoma: has the cancer of gastric cardia an influence on the rising incidence of oesophageal adenocarcinoma?. Scand J Gastroenterol 35 (2000) 1082-1086
5. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
6. Brewster D.H., Fraser L.A., McKinney P.A., and Black R.J. Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland. Br J Cancer 83 (2000) 387-390
7. Newnham A., Quinn M.J., Babb P., et al. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther 17 (2003) 655-664
8. Eloubeidi M.A., Mason A.C., Desmond R.A., et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. Am J Gastroenterol 98 (2003) 1627-1633
9. Anderson L.A., Watson R.G., Murphy S.J., et al. Risk factors for Barrett's Oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 13 (2007) 1585-1594
10. Conio M., Cameron A.J., Romero Y., et al. Secular trends in the epidemiology and outcome of Barrett's Oesophagus in Olmsted County, Minnesota. Gut 48 (2001) 304-309
11. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129 (2005) 1825-1831
12. Sampliner R.E. A population prevalence of Barrett's esophagus-finally. Gastroenterology 129 (2005) 2101-2103
13. Somerville M., Garside R., Pitt M., et al. Surveillance of Barrett's oesophagus: is it worthwhile?. Eur J Cancer 44 (2008) 588-599
14. British Society Of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. A Report of the Working Party of the British Society of Gastroenterology (August 2005). http://www.bsg.org.uk/pdf_word_docs/Barretts_Oes.pdf Accessed April 2009
15. Wang K.K., Sampliner R.E., and The Practice Parameters Committee of the American College of Gastroenterology. Practice Guidelines. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103 (2008) 788-797
16. Macdonald C.E., Wicks A.C., and Playford R.J. Final results from 10 year cohort of patients undergoing surveillance for Barrett's Oesophagus: observational study. BMJ 321 (2000) 1252-1255
17. Cook M.B., Wild C.P., Everett S.M., et al. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16 (2007) 2090-2096
18. Soni A., Sampliner R.E., and Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?. Am J Gastroenterol 95 (2000) 2086-2093
19. Sharma P., and Sidorenko E.I. Are screening and surveillance for Barrett's oesophagus really worthwhile?. Gut 54 suppl 1 (2005) i27-i32
20. Spechler S.J., and Barr H. Review article: screening and surveillance of Barrett's oesophagus: what is a cost-effective framework?. Aliment Pharmacol Ther 19 suppl 1 (2004) 49-53
21. Inadomi J.M., and Rubenstein J.H. The cost-effectiveness of screening and surveillance to decrease mortality from esophageal adenocarcinoma. In: Sharma P., and Sampliner R. (Eds). Barrett's esophagus and esophageal adenocarcinoma. 2nd ed. (2009), Wiley-Blackwell, Hoboken, NJ 124-138
22. Rubenstein J.H., Vakil N., and Inadomi J.M. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther 22 (2005) 135-146
23. Rubenstein J.H., and Inadomi J.M. Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol 40 (2006) 109-115
24. Inadomi J.M., Sampliner R., Lagergren J., et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138 (2003) 176-186
25. Gerson L.B., Groeneveld P.W., and Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2 (2004) 868-879
26. Rubenstein J.H., Inadomi J.M., Brill J.V., et al. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol 5 (2007) 312-318
27. Gerson L., and Lin O.S. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol 5 (2007) 319-325
28. Nietert P.J., Silverstein M.D., Mokhashi M.S., et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc 57 (2003) 311-318
29. Roorda A.K., Marcus S.N., and Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus 20 (2007) 516-522
30. Ganz R.A., Overholt B.F., Sharma V.K., et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc 68 (2008) 35-40
31. Caygill C.P., Watson A., Reed P.I., et al. Characteristics and regional variations of patients with Barrett's oesophagus in the UK. Eur J Gastroenterol Hepatol 15 (2003) 1217-1222
32. Vieth M., Schubert B., Lang-Schwarz K., et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 38 (2006) 1201-1205
33. Gatenby P.A., Caygill C.P., Ramus J.R., et al. Short segment columnar-lined oesophagus: an underestimated cancer risk?. A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol 19 (2007) 969-975
34. Leiferman J.A., and Pheley A.M. The effect of mental distress on women's preventive health behaviors. Am J Health Promot 20 (2006) 196-199
35. Brett J., Bankhead C., Henderson B., et al. The psychological impact of mammographic screening. A systematic review. Psychooncology 14 (2005) 917-938
36. Gerson L.B., Ullah N., Hastie T., et al. Does cancer risk affect health-related quality of life in patients with Barrett's esophagus?. Gastrointest Endosc 65 (2007) 31-35
37. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett's oesophagus: a reaffirmation. Hum Pathol 32 (2001) 368-378
38. Ormsby A.H., Petras R.E., Henricks W.H., et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 51 (2002) 671-676
39. Eloubeidi M.A., and Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 95 (2000) 1881-1887
40. Gerson L.B., Ullah N., Hastie T., et al. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 534-536
41. Macran S., Wileman S., Barton G., et al. The development of a new measure of quality of life in the management of gastro-oesophageal reflux disease: the Reflux questionnaire. Qual Life Res 16 (2007) 331-343
42. NHS Information Centre & Office for National Statistics. Breast Screening Programme England 2006-07. http://www.ic.nhs.uk/webfiles/publications/breastscreening0607/Breast%20Screening%20Bulletin%202006-07.pdf Accessed April 2009
43. Shaheen N.J., Inadomi J.M., Overholt B.F., et al. What is the best management strategy for high grade dysplasia in Barrett's oesophagus?. A cost effectiveness analysis. Gut 53 (2004) 1736-1744
44. Vij R., Triadafilopoulos G., Owens D.K., et al. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 60 (2004) 739-756
45. Murray L., Sedo A., Scott M., et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 55 (2006) 1390-1397
46. Lao-Sirieix P., Lovat L., and Fitzgerald R.C. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res 13 (2007) 659-665
47. Fitzgerald R.C. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55 (2006) 1810-1820
48. Galipeau P.C., Li X., Blount P.L., et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4 (2007) e67
49. Chao D.L., Sanchez C.A., Galipeau P.C., et al. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res 14 (2008) 6988-6995
50. Peters C.J., and Fitzgerald R.C. Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther 25 (2007) 1253-1269
51. Quera R., O'Sullivan K., and Quigley E.M. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?. Endoscopy 38 (2006) 162-169
52. Lagergren J., Ye W., Bergström R., et al. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA 284 (2000) 961-962
53. Pharoah P.D., Antoniou A.C., Easton D.F., et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358 (2008) 2796-2803
54. Lao-Sirieix P., Rous B., O'Donovan M., et al. Non-endoscopic immunocytological screening test for Barrett's oesophagus. Gut 56 (2007) 1033-1034
55. Sir Liam Donaldson, Chief Medical Officer. On the State of Public Health: Annual Report of the Chief Medical Officer 2007. Department of Health, 2008. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/AnnualReports/DH_086176 Accessed April 2009
56. Jankowski J., and Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 332 (2006) 1512
57. Heath E.I., Canto M.I., Piantadosi S., et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99 (2007) 545-557